0001209191-17-009043.txt : 20170209 0001209191-17-009043.hdr.sgml : 20170209 20170209160304 ACCESSION NUMBER: 0001209191-17-009043 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170207 FILED AS OF DATE: 20170209 DATE AS OF CHANGE: 20170209 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: aTYR PHARMA INC CENTRAL INDEX KEY: 0001339970 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 203435077 STATE OF INCORPORATION: DE BUSINESS ADDRESS: STREET 1: 3545 JOHN HOPKINS COURT, STE #250 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-731-8389 MAIL ADDRESS: STREET 1: 3545 JOHN HOPKINS COURT, STE #250 CITY: SAN DIEGO STATE: CA ZIP: 92121 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Amanullah Ashraf CENTRAL INDEX KEY: 0001670631 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37378 FILM NUMBER: 17587538 MAIL ADDRESS: STREET 1: C/O ATYR PHARMA, INC. STREET 2: 3545 JOHN HOPKINS COURT, SUITE 250 CITY: SAN DIEGO STATE: CA ZIP: 92121 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-02-07 0 0001339970 aTYR PHARMA INC LIFE 0001670631 Amanullah Ashraf 3545 JOHN HOPKINS COURT, SUITE #250 SAN DIEGO CA 92121 0 1 0 0 Vice President, Manufacturing Employee Stock Option (right to buy) 3.30 2017-02-07 4 A 0 35000 0.00 A 2027-03-07 Common Stock 35000 35000 D Restricted Stock Unit 2017-02-07 4 A 0 10000 0.00 A Common Stock 10000 10000 D The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning March 7, 2017, such that this option will be fully exercisable on February 7, 2021. This option is subject to accelerated vesting upon termination without cause upon change of control of the issuer. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units (RSUs) are scheduled to vest in three equal annual installments beginning on February 7, 2018, such that the RSUs will fully vest on February 7, 2020. This grant is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Nancy D. Krueger, attorney-in-fact 2017-02-09